Last reviewed · How we verify
Pleural Malignant Effusions — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Blenoxane | BLEOMYCIN | Bristol-Myers Squibb | Cytoprotective Agent | Aspartyl/asparaginyl beta-hydroxylase | 1973-01-01 | |
| Valchlor | MECHLORETHAMINE | Recordati | Alkylating Drug [EPC] | 1949-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Pleural Malignant Effusions
- Recordati · 1 drug in Pleural Malignant Effusions
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pleural Malignant Effusions:
- Pleural Malignant Effusions treatment updates — RSS
- Pleural Malignant Effusions treatment updates — Atom
- Pleural Malignant Effusions treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pleural Malignant Effusions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pleural-malignant-effusions. Accessed 2026-06-10.
Related
- Pleural Malignant Effusions full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing